Log in
This hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing.

NASDAQ:MNPR - Monopar Therapeutics Stock Price, Forecast & News

-1.03 (-5.84 %)
(As of 01/24/2020 08:00 AM ET)
Today's Range
Now: $16.62
50-Day Range N/A
52-Week Range
Now: $16.62
Volume21,600 shs
Average Volume39,968 shs
Market Capitalization$176.01 million
P/E RatioN/A
Dividend YieldN/A
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that has completed Phase II for the treatment of chemoradiation-induced severe oral mucositis; Camsirubicin, a proprietary doxorubicin analog that is in Phase II clinical trial for the treatment of adult and pediatric solid, and blood cancers; and MNPR-101, a humanized monoclonal antibody for treating cancer. The company has a collaboration with Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MNPR



Sales & Book Value

Annual SalesN/A



Market Cap$176.01 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MNPR News and Ratings via Email

Sign-up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.


Simple Options Trading for Beginners retails on Amazon for $19.95 and has 4 out of 5 stars. It was written by a stock market trading veteran with over 44 years of experience. Because of a special promotion, this book is 100% FREE for you today.

Monopar Therapeutics (NASDAQ:MNPR) Frequently Asked Questions

What is Monopar Therapeutics' stock symbol?

Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."

Has Monopar Therapeutics been receiving favorable news coverage?

News headlines about MNPR stock have been trending very positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Monopar Therapeutics earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Monopar Therapeutics.

Who are some of Monopar Therapeutics' key competitors?

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Applied Materials (AMAT), Splunk (SPLK), Coupa Software (COUP), Costco Wholesale (COST), Cara Therapeutics (CARA), Broadcom (AVGO), Arena Pharmaceuticals (ARNA), Anika Therapeutics (ANIK), Advanced Micro Devices (AMD) and Analog Devices (ADI).

Who are Monopar Therapeutics' key executives?

Monopar Therapeutics' management team includes the folowing people:
  • Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc, Co-Founder, CEO, Pres & Director (Age 36)
  • Ms. Kim R. Tsuchimoto, CFO, Sec. & Treasurer (Age 57)
  • Dr. Andrew P. Mazar, Exec. VP of R&D, Chief Scientific Officer and Director (Age 58)
  • Dr. Patrice P. Rioux, Acting Chief Medical Officer (Age 69)

When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

When does the company's quiet period expire?

Monopar Therapeutics' quiet period expires on Tuesday, January 28th. Monopar Therapeutics had issued 1,111,112 shares in its public offering on December 19th. The total size of the offering was $8,888,896 based on an initial share price of $8.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Monopar Therapeutics' stock price today?

One share of MNPR stock can currently be purchased for approximately $16.62.

How big of a company is Monopar Therapeutics?

Monopar Therapeutics has a market capitalization of $176.01 million. Monopar Therapeutics employs 4 workers across the globe.View Additional Information About Monopar Therapeutics.

What is Monopar Therapeutics' official website?

The official website for Monopar Therapeutics is http://www.monopartx.com/.

How can I contact Monopar Therapeutics?

Monopar Therapeutics' mailing address is 5 REVERE DRIVE SUITE 200, NORTHBROOK IL, 60062. The company can be reached via phone at 614-395-8936 or via email at [email protected]

MarketBeat Community Rating for Monopar Therapeutics (NASDAQ MNPR)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Monopar Therapeutics and other stocks. Vote "Outperform" if you believe MNPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel